Nano Interface Technology, Inc. to Present at Medtech Insight's ''Investment In Innovation'' Conference

Nano Interface Technology, Inc. to Present at Medtech Insight's 'Investment In Innovation' Conference
February 03, 2005

IRVINE, Calif.--(BUSINESS WIRE)--Feb. 3, 2005--Nano Interface Technology, Inc. will be presenting on February 11, 2005 at Medtech Insight's Prestigious "Investment In Innovation (In3): A Preview of Early-Stage Medical Technology Companies" Conference, taking place February 10-11, 2005 at the Hyatt Regency Irvine in Irvine, California.
Nano Interface Technology, Inc. (NITI), established in 1997, provides major improvement in medical devices using well-proven economical platform technology. NITI has developed a cutting edge nanotechnology-derived coating process for medical devices. NITI has a unique competitive and technological advantage over other Nanotech Companies in the production of ultra-pure nanoparticles of multi-metals. The first product developed by the NITI is the nano-biomaterials for coating of medical devices. For the last 20 years, the lifespan of orthopedic and dental implants has been 10 to 12 years and revision rate has been 17%. The existing plasma sprayed coating technology for implants is very costly and has several disadvantages. The economical ultra-pure nano-size coating process developed by NITI has the potential to increase the lifespan of these implants from 12 years to 20 years and to reduce the overall revision rate from 17% to much less. Since these biomaterials are currently used in implants, therefore, implants developed using purer biomaterials will easily capture the market.
NITI has completed the research and the Company will carry out in vivo studies to demonstrate the efficacy of these devices in the next 3 years. The Company plans to license its technology to the existing players in the dental implants business. NITI will provide coatings for the orthopedic implants to the manufacturers for higher growth in revenue. The market success in the dental application will validate the benefits of nanotechnology-derived implants. This will help the NITI to penetrate into the orthopedic market easily. The worldwide market size of the orthopedic and dental implants is $15B per year with 15% growth rate. The current growth rate of 15% has a potential to increase to 25%. This is because several painkillers for arthritis are pulled from the market which will lead to more hip and knee replacements. The reduction in the revision rate of hip and knee implants from 17% to 12% has the potential of saving $825M per year in the US alone. The Company's product is validated through an extensive review by the NIH Nanotechnology Review Panel which will provide additional revenue to the company. For more information, please visit www.nanointerfacetech.com. Certain statements included in this press release may constitute forward-looking statements.
Now a division of Windhover Information Inc., Medtech Insight is the leading provider of business information and market intelligence for the medical technology marketplace. To register for In3 Irvine or for more information on Medtech Insight, please call Scott Pantel at (949) 219-0150 or (888) 290-2225 toll-free in the U.S., e-mail sales@medtechinsight.com, or visit www.medtechinsight.com.